Cancer cachexia is responsible for the death of approximately 20% of patients. Myostatin is a master negative regulator of skeletal muscle mass. If the role of myostatin in cancer cachexia is now well established in murine models, no study has focused on muscle expression of Myostatin in relation to the degree of cachexia. the hypothesize is that muscle Myostatin a biological marker of cachexia in patients with cancer of digestive system. The main objective is to compare skeletal muscle Myostatin messenger RiboNucleic Acid (mRNA) level as a function of cachexia in cancer of digestive system patients. Myostatin messenger RiboNucleic Acid (mRNA) level will be determined in a muscle sample taken during the resection under general anaesthesia. Skeletal muscle index will be determined before surgery, 3 and 6 months after surgery. Muscle strength of the lower and upper limbs will be determined before resection, at 1 month, 3 months and 6 months postoperatively. Blood sampling will also be performed on these 4 occasions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
3
Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
CHU Saint-Etienne
Saint-Etienne, France
Correlation between skeletal muscle and degree myostatin
Evaluate correlation between skeletal muscle force/index and degree myostatin. Skeletal muscle force/index will be determinated by skeletal muscle force/index results. Degree myostatin will be determinated by blood samples with Enzyme Linked ImmunoSorbent Assay (ELISA) method.
Time frame: Day 1
Correlation between skeletal muscle force and index before resection surgery
Evaluate Correlation between skeletal muscle force and index before resection surgery to estimate the extent of cachexia-induced muscle dysfunction by results tests.
Time frame: Baseline from 7 months
Correlation between level of myostatin muscular expression and degree myostatin
Evaluate correlation between level of myostatin muscular expression and degree myostatin. Level of myostatin muscular expression will be determinated by muscle biopsy. Degree myostatin will be determinated by blood samples with Enzyme Linked ImmunoSorbent Assay (ELISA) method.
Time frame: Month 2
Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery
Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.
Time frame: Month 2
Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery
Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.
Time frame: Month 4
Correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery
Determinate correlation between level of myostatin muscular expression and skeletal muscle force and index after resection surgery.
Time frame: Month 7
Analysis level of myostatin muscular expression and blood samples results
Analysis level of myostatin muscular expression and blood samples results according to cancer stage, neoadjuvant treatment and chemotherapy.
Time frame: Month 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.